Oncolytic viral (OV) therapy has been considered as a promising treatment modality for brain tumors. Vasculostatin, the fragment of brain-specific angiogenesis inhibitor-1, shows anti-angiogenic activity against malignant gliomas. Previously, a vasculostatinexpressing oncolytic herpes simplex virus-1, Rapid Antiangiogenesis Mediated By Oncolytic virus (RAMBO), was reported to have a potent antitumor effect. Here, we investigated the therapeutic efficacy of RAMBO and cilengitide, an integrin inhibitor, combination therapy for malignant glioma. In vitro, tube formation was significantly decreased in RAMBO and cilengitide combination treatment compared with RAMBO or cilengitide monotherapy. Moreover, combination treatment induced a synergistic suppressive effect on endothelial cell migration compared with the control virus. RAMBO, combined with cilengitide, induced synergistic cytotoxicity on glioma cells. In the caspase-8 and -9 assays, the relative absorption of U87DEGFR cell clusters treated with cilengitide and with RAMBO was significantly higher than that of those treated with control. In addition, the activity of caspase 3/7 was significantly increased with combination therapy. In vivo, there was a significant increase in the survival of mice treated with combination therapy compared with RAMBO or cilengitide monotherapy. These results indicate that cilengitide enhanced vasculostatinexpressing OV therapy for malignant glioma and provide a rationale for designing future clinical trials combining these two agents.
INTRODUCTION
Glioblastoma multiforme is the most frequent primary malignant brain tumor in adults. Pathologically, glioblastoma multiforme is characterized by features of malignancy, including marked neovascularity, rapid cell proliferation, infiltrative cell migration and extensive necrosis. The median survival of patients remains at 14-16 months and the 5-year survival rate is o3%, 1 even if the most aggressive treatment is attempted. Given the poor prognosis of this disease, there is a desperate need for novel methods of intervention, including oncolytic therapy and molecular targeted therapy. 2 Oncolytic viral (OV) therapy is an emerging biological treatment modality that exploits the tumor-specific properties of some viruses. 3 Oncolytic herpes simplex viruses (HSVs) are genetically engineered to replicate selectively in and lyse tumor cells but cause minimal damage to normal tissue. Vasculostatin (Vstat120) is the extracellular fragment of brain-specific angiogenesis inhibitor 1 and has been shown to be a potent antiangiogenic and antitumorigenic factor. 4 We have created an armed oncolytic HSV-1 that expresses Vstat120 under the control of an immediate early IE4/5 HSV promoter. 5 On the basis of its potent and rapid induction of antiangiogenic Vstat120, we named this virus Rapid Antiangiogenesis Mediated By Oncolytic virus (RAMBO). Treatment of mice bearing intracranial and subcutaneous gliomas revealed a significant increase in the antitumor efficacy of RAMBO compared with the control virus.
Integrins control the attachment of cells to the extracellular matrix and participate in cellular defense against genotoxic assaults. 6 Integrins are expressed in tumor cells and tumor endothelial cells, [7] [8] [9] and they have important roles in angiogenesis and invasion in glioma. [10] [11] [12] The integrins avb3 and avb5 regulate cell adhesion, 13, 14 and inhibitors of these integrins suppress tumor growth in certain pre-clinical models. 15 Therefore, integrins have attracted attention as potential therapeutic targets in glioma. Several integrin-targeted drugs are in clinical trials as potential compounds for the treatment of cancer. Among them, cilengitide (EMD121974) is a novel integrin antagonist for the treatment of glioblastoma. 16 Cilengitide is currently being assessed in phase III trials for glioblastoma patients and phase II trials for other types of cancers, with promising therapeutic outcomes reported to date. Several preclinical studies have shown an enhanced antitumor effect of cilengitide when administered in combinatorial therapeutic regimens. [17] [18] [19] [20] Previously, we presented an in vivo study of OV therapyinduced changes in tumor blood vessels and the impact of modulating tumor vasculature on the efficacy of OV therapy in a rat glioma model. 21 OV treatment of rat gliomas increased the permeability of the tumor vasculature, tumor inflammation and leukocyte infiltration. 22, 23 Pretreatment of gliomas with cilengitide reduced inflammation, vascular hyperpermeability and leukocyte infiltration of tumor tissue following treatment with an oncolytic virus and enhanced the anticancer efficacy of OV treatment by increasing viral propagation in tumors. In this study, we demonstrate RAMBO and cilengitide combination treatment of glioma. An evaluation of the cytotoxic mechanism revealed the Immunocytological analysis U251, Gli36 and U87DEGFR glioma cells were seeded onto 4-Chamber Polystyrene Vessel Tissue Culture Treated Glass Slides (BD Falcon, Franklin Lakes, NJ, USA) and incubated overnight. For immunofluorescence, the cells were fixed in 4% paraformaldehyde in phosphate-buffered saline (PBS) for 15 min. After the cells were fixed, they were rinsed three times with PBS. Nonspecific binding was blocked by incubation in a blocking buffer containing 2% bovine serum albumin (BSA) in PBS for 30 min at room temperature. The cells were incubated overnight at 4 1C with a mouse monoclonal anti-human integrin avb3 antibody (CHEMICON MAV1976) or mouse monoclonal anti-human integrin avb5 antibody (Abcam, Cambridge, MA, USA), which were diluted 1:100 and 1:500 in blocking buffer, respectively.
The cells were washed in blocking buffer 3 times for 5 min before incubation with a secondary anti-mouse CY3-conjugated antibody (Jackson ImmunoResearch Laboratories, Inc., West Grove, PA, USA) diluted 1:300 in blocking buffer for 2 h at room temperature in the dark. After three washes in PBS, the cells were counterstained with 4 0 , 6-diamino-2-phenylindole (1:500; 100 ng ml À 1 ; Invitrogen, Carlsbad, CA, USA) for 20 min at room temperature. The slides were washed three times in PBS and mounted.
Tube formation assay
An Angiogenesis Assay Kit (Kurabo, Osaka, Japan) was used according to the manufacturer's instructions. Briefly, human umbilical vein endothelial cells (HUVECs), co-cultured with neonatal normal human dermal fibroblasts, 26 were treated with cilengitide (0.1 mM), RAMBO (5.0 Â 10 2 plaqueforming units (pfu)) and vascular endothelial growth factor (VEGF) (10 ng ml À 1 ). Suramin (50 mM) was used as a positive anti-angiogenic control. The medium was changed every 3 days. After 10 days, the dishes were washed with PBS and fixed with 70% ethanol at 4 1C. After the fixed cells were rinsed three times with PBS, the cells were incubated with mouse anti-human CD31 in PBS containing 1% BSA for 60 min. After washing three times with 1% BSA-PBS, the cells were incubated with a goat anti-mouse IgG AlkP conjugate. Metal-enhanced 3, 3 0 -diaminobenzidine-tetrahydrochloride was used as the substrate, the reaction yielding a dark reddish-brown insoluble end-product. Finally, the cells were washed five times with PBS and viewed under a microscope (BZ-8000; Keyence, Osaka, Japan). Tube formation was counted under high magnification ( Â 20) , and the average tube area in three hot spots was taken as the tube formation per view field. Tube formation was counted in at least three dishes.
Endothelial cell migration assay (scratch wound assay) U251 glioma cells were infected with RAMBO or HSVQ (multiplicity of infection (MOI): 2), and after 14 h, the conditioned medium (CM) was harvested, cellular debris was removed by centrifugation and free floating viral particles were removed by further centrifugation at approximately 28 000 g for 1 h. For the endothelial cell migration assays, early passage human dermal microvascular endothelial cells (HMVEC-d; passage 3) were purchased from Lonza (Basel, Switzerland). The cells were used between passages 4 and 6, and they were maintained in endothelial growth media. HMVEC-d were plated onto a 24-well dish and allowed to grow to confluence. A thin line was made with a sterile 1000-ml pipette tip in the middle of the well, and they were incubated with CM derived from U251 glioma cells (prepared in 2% FBS DMEM as described previously) and the indicated concentration of cilengitide was added. HMVEC-d were incubated for 12 h at 37 1C to allow cellular migration into the denuded area, and they were assessed by phase contrast microscopy.
Virus yield assay
To assess virus yield, U87DEGFR glioma cells were seeded on six-well plates at 3.0 Â 10 5 cells per well. The cells were infected with RAMBO at an MOI of 0.1, and after 3 h of infection, we added either PBS or cilengitide (10 mM). At 36 h after infection, the glioma cells were harvested by scraping and lysed by freezing and thawing three times. Cellular debris was removed by centrifugation, and the number of infectious viral particles (pfu) in the cells was assessed using a standard viral titration assay.
Cytotoxicity assays
The cytotoxicity of U251, Gli36 and U87DEGFR glioma cells was analyzed by the water-soluble tetrazolium (WST)-1 quantitative colorimetric assay for cell survival according to the manufacturer's instructions (Roche Molecular Biochemicals, Mannheim, Germany). This assay detects living, but not dead, cells, and the generated signal depends on the degree of cell activation. We seeded 1.0 Â 10 4 cells/well in 96-well plates, and they were left to attach at 37 1C. Subsequently, the cells were treated with saline, cilengitide, RAMBO or RAMBO and cilengitide combined. The cell lines were treated with the indicated concentrations of cilengitide or the indicated MOIs. Cell survival was measured at the indicated time points by adding the reaction solution (10 ml) to 100 ml of culture medium per well. The samples were then incubated for an additional 60-150 min at 37 1C in a humidified atmosphere of 5% CO 2 and 95% air. The absorption of the samples was measured with a Thermo Scientific Multiskan FC Microplate Photometer (Thermo Fisher Scientific, Inc., Vantaa, Finland) at 450 nm wavelength using a 620 nm reference filter. The amount of formazan dye formed directly correlates to the number of metabolically active, viable cells. After subtraction of the background absorption, the mean value of the untreated control cells was set as 100%.
Caspase assays
Activity assay for caspase-8 and -9. Caspase-8 and -9 levels were measured using a FLICE/Caspase-8 Colorimetric Assay Kit and Caspase-9 Colorimetric Assay Kit (BioVision, Mountain View, CA, USA), respectively, according to the manufacturer's instructions. Briefly, U87DEGFR glioma cells were seeded in five 10-cm dishes (1.0 Â 10 6 cells per dish), and after confirmation of their attachment, they were treated with culture medium containing cilengitide (10 mM), RAMBO (MOI 0.1) and with a combination of RAMBO (same as above) and cilengitide in triplicate. At 16 h after adding the reagents and oncolytic virus, the cells were harvested and lysed using a cell lysis buffer. We centrifuged the cell lysate and harvested the supernatant, and the caspase solutions were then added. After incubation with these substrates for 1-2 h, the absorption of each group was measured by using FlexStation 3 (Molecular Devices, Tokyo, Japan).
Activity assay for caspase-3/7. Caspase-3/7 activity levels were measured using the CellEvent Caspase-3/7 Green Detection Reagent (Invitrogen, Carlsbad, CA, USA) according to the manufacturer's protocol. Briefly, U87DEGFR glioma cells were seeded in 96-well plates (10 000 cells per well), and after confirmation of their attachment, they were treated with culture medium containing cilengitide (10 mM), RAMBO (MOI 0.1) and with a combination of RAMBO (same as above) and cilengitide in triplicate. The caspase solution was added at 16 h after adding the reagents and oncolytic virus. Before and after incubation with these substrates, the fluorescence intensity of each well was measured using FlexStation 3. We determined the caspase activity by measuring the fluorescence intensity and subtracted the background fluorescence of each well.
Animal surgery and treatment
All animal experiments were performed according to the guidelines of the Subcommittee on Research Animal Care of the Okayama University and were approved by the Institutional Review Board. Athymic nude mice (6-8-week-old balb/c-nu/nu; CLEA Japan, Inc., Tokyo, Japan) were used for Cilengitide enhances anti-glioma efficacy of oncolytic viral therapy K Fujii et al all studies. For intracranial tumor studies, the mice were anesthetized with ketamine and somnopentyl and fixed in a stereotactic apparatus (Narishige, Tokyo, Japan) with their skull exposed. A burr hole was made at1 mm posterior and 3 mm lateral from the bregma, and a Hamilton syringe (Hamilton, Reno, NV, USA) was then inserted to a depth of 3 mm below the brain surface. Then, 2 ml of 2.0 Â 10 5 U87DEGFR glioma cells were slowly injected into the brain at a rate of 1 ml per min. The syringe was kept in place for 5 min after the injection and then slowly retracted to minimize backflow. We cleaned the skull, sealed the hole with bone wax and sutured the incision. Seven days after the implantation of the U87DEGFR cells (10 5 cells), anesthetized mice were stereotaxically inoculated with 5.0 Â 10 4 pfu of RAMBO at the same location. Nine days after the implantation of the U87DEGFR cells, the mice were treated with either cilengitide (200 mg per 100 ml PBS) or PBS intraperitoneally three times a week. The animals were observed daily and were killed when they showed signs of morbidity.
Statistical analysis
The Mann-Whitney U test was used to analyze changes in cell death, HMVEC-d migration assay, and caspase assay data. Data are presented as the means ± s.e. P-valueso0.05 were considered statistically significant in the Mann-Whitney U test. Kaplan-Meier curves were compared using the log-rank test. All statistical analysis was performed using SPSS statistical software (version 20; SPSS, Inc., Chicago, IL, USA).
RESULTS
Antiangiogenic effect of combination treatment in the tube formation assay To investigate the antiangiogenic effect of RAMBO and cilengitide, the tube formation assay was performed using HUVECs cocultured with fibroblasts. When HUVECs were cultured in the presence of VEGF, efficient tube formation was observed. Conversely, an anti-VEGF drug (suramin: 50 mM) efficiently inhibited tube formation. Both RAMBO and cilengitide inhibited tube formation in HUVECs. Moreover, RAMBO and cilengitide combination treatment significantly inhibited tube formation compared with RAMBO or cilengitide monotherapy. Quantitative analysis of tube area confirmed that RAMBO and cilengitide efficiently inhibited in vitro angiogenesis, and combination treatment reduced angiogenesis more intensively than monotherapy (RAMBO and cilengitide combination: 8.4 Â 10 3 ±2.1 Â 10 2 pixels; Immunocytochemical analysis of avb3 and avb5 integrin expression in glioma cell lines Immunofluorescence assays were conducted to determine the expression of avb3 and avb5 integrins in U251, Gli36 and U87DEGFR glioma cell lines. Most of these cultured cell lines were immunopositive for avb3 and avb5. The percentage of cells staining for avb3 and avb5 was as follows: U251: avb3 95.3 ± 1.3%, avb5 93.4 ± 6.7%; Gli36: avb3 98.3 ± 2.9%, avb5 97.0 ± 5.2%; U87dEGFR: avb3 95.1±4.3% avb5 87.1±6.0% (Supplementary Figure S1) . 
Cytotoxic effect of combination treatment
The cytotoxic effect of RAMBO and cilengitide on glioma cells was investigated in vitro. Figure 4 shows the results of the WST-1 assay, which demonstrate the cytotoxicity effect of RAMBO and cilengitide. Glioma cell lines were incubated with the indicated concentration of cilengitide or the indicated MOI. After 36 h, cell viability was assessed by the WST-1 proliferation/viability assay. Cell survival after a 36-h incubation was decreased more by treatment with a high MOI than with cilengitide. Moreover, the addition of cilengitide enhanced the reduction of cell viability. This result indicated that the combination of RAMBO with cilengitide induced additive or synergistic cytotoxicity.
Apoptotic effect of RAMBO and cilengitide combination treatment U87DEGFR glioma cells were treated with cilengitide (10 mM), RAMBO (MOI 0.1) and RAMBO and cilengitide combined (same as above). At 16 h after infection with RAMBO and 13 h after adding cilengitide or PBS, glioma cells were harvested and the activity of caspase-8, -9 and -3/7 was evaluated. In the caspase-8 assay, the relative absorption (RA) of U87DEGFR cell clusters treated with cilengitide was significantly higher than that of those treated with control (caspase-8: 0.33±0.065 RA vs 0.27±0.054 RA, P ¼ 0.043) (Figure 5a ). In the caspase-9 assay, the RA of U87DEGFR cell clusters treated with RAMBO was significantly higher than that of those treated with control (0.33 ± 0.027 vs 0.029 ± 0.029, P ¼ 0.043; Figure 5b ).
The activity of caspase-3/7 was also increased in treated cells; especially, a significant increase of caspase-3/7 activity was observed in cells treated with cilengitide and with RAMBO and cilengitide combined. Moreover, there was a significant increase in caspase-3/7 activity in cells treated with combination therapy compared with RAMBO monotherapy, cilengitide monotherapy and untreated cells (P ¼ 0.0008, P ¼ 0.0117 and P ¼ 0.0008, respectively; Figure 6 ).
Effect of cilengitide treatment on the therapeutic efficacy of RAMBO in a xenograft mouse model The antitumor effect of RAMBO, cilengitide and RAMBO and cilengitide combined was tested in mice bearing intracerebral glioma (U87DEGFR). Kaplan-Meier survival curves were used to assess the survival time of the U87DEGFR mouse glioma model treated with PBS, cilengitide, RAMBO and RAMBO and cilengitide combined. There was a significant increase in the survival of mice treated with combination therapy compared with RAMBO monotherapy, cilengitide monotherapy or untreated mice (median survival ¼ 38. 5, 29, 19 , and 19 days, respectively; Po0.005, Po0.001, and Po0.001, respectively; Figure 7 ). . Induction of Caspase-8 and -9 by treatment with rapid antiangiogenesis mediated by oncolytic virus (RAMBO), cilengitide and RAMBO and cilengitide combined in vitro. (a) Caspase-8 activity assay. U87DEGFR glioma cells were treated with cilengitide (10 mM), RAMBO (multiplicity of infection 0.1) and RAMBO and cilengitide combined (same as above). At 16 h after infection with RAMBO and 13 h after adding cilengitide or phosphate-buffered saline, caspase activity was evaluated in the cells using a FLICE/Caspase-8 Colorimetric Assay Kit. There was a significant increase in caspase-8 activity in glioma cells treated with cilengitide compared with those of control. The symbol (*) show a significant increase in caspase-8 activity. (b) Assay of caspase-9 activity. U87DEGFR glioma cells were treated as mentioned and evaluated using a Caspase-9 Colorimetric Assay Kit. There was a significant increase in caspase-9 activity in glioma cells treated with RAMBO compared with those of (a); *P ¼ 0.043.
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DISCUSSION
Our results indicate that the combination of RAMBO and cilengitide significantly inhibited tube formation compared with RAMBO or cilengitide monotherapy. Moreover, RAMBO and cilengitide combination treatment induced a synergistic suppressive effect on endothelial cell migration. The addition of cilengitide enhanced the reduction of cell viability and a significant increase of caspase-8, -9 and -3/7 activity was observed in cells treated with cilengitide and with RAMBO and cilengitide combined. Furthermore, the survival time of mice bearing intracerebral glioma treated with combination therapy was significantly increased compared with monotherapy.
The advantage of the RAMBO virus on OV therapy We have shown that the reduction of tumoral blood vessel density by a single dose of cilengitide treatment before oncolytic HSV-1 treatment reduced oncolytic virus-induced hyperpermeability and tumor inflammation, and prolonged tumoral viral propagation, thereby enhancing the antitumor efficacy of the oncolytic virus. 21 In addition, we showed that RAMBO had a significantly greater antitumor effect compared with OV treatment alone. 5 We suggested that the increased antitumor efficacy of RAMBO might be attributed to its ability to counter oncolytic virusinduced angiogenic changes in the tumor microenvironment. Certainly, in our experiments, we could have the antiangiogenic effect and apoptotic effect following treatment with RAMBO as single treatment.
The advantage of combination therapy with cilengitide Several preclinical studies have shown an enhanced antitumor effect of cilengitide when administered in combinatorial therapeutic regimens. [17] [18] [19] [20] Mikkelsen et al. 27 demonstrated that cilengitide dramatically amplified the efficacy of radiation therapy in an animal glioma model. We demonstrated the enhanced therapeutic efficacy of an oncolytic virus on experimental glioma following pretreatment with cilengitide. 21 OV treatment of experimental rat gliomas results in vascular hyperpermeability of the tumor. In this study, we reported the effects of a novel oncolytic HSV virus and the systemic injection of cilengitide. In addition, we also revealed that there was synergistic effect between cilengitide and viral injection. Especially, the combination of RAMBO with cilengitide induced a synergistic suppressive effect on endothelial cell migration compared with combining cilengitide with the CM of HSVQ-treated cells. Future studies will elucidate the relationship between Vstat120 expression and cilengitide.
A role for apoptosis in combination treatment with oncolytic virus and cilengitide Previously, the cytotoxic effect of cilengitide was clearly shown. Recently, similar changes in HUVECs have been reported for S 36578-2, a novel RGD mimetic that selectively activates the avb3 and avb5 integrins. 28 This compound induces cell detachment and apoptosis by the direct activation of caspase-8. 29 In our study, cilengitide inhibited integrin binding and activated caspase-8. This caspase-8 activation effect of cilengitide would enhance the effect of other cytotoxic therapies. On the other hand, a previous study showed the induction of increased mitochondrial membrane permeability, a surrogate marker for apoptosis, in an oncolytic virus derived from HSV-1. 30 Prominent and early caspase-9 processing is compatible with the mitochondrial triggering of the caspase cascade, as reported previously. In our data, especially, a significant increase of caspase -3/7 activity was observed in cells treated with both RAMBO and cilengitide. This combination between the mitochondriadependent pathway with caspase-9 activation and the death-receptor pathway, including caspase-8 activation, might be more efficient for inducing apoptosis than a single pathway (Figure 8 ). Figure 6 . Induction of caspase-3/7 following treatment with rapid antiangiogenesis mediated by oncolytic virus (RAMBO), cilengitide and RAMBO and cilengitide combined in vitro. Assay of caspase-3/7 activity. U87DEGFR glioma cells were treated with cilengitide, RAMBO and RAMBO and cilengitide combined (same as above). At 16 h after infection with RAMBO and 13 h after adding cilengitide or phosphate-buffered saline, caspase activity was evaluated in the cells using the CellEvent Caspase-3/7 Green Detection Reagent. Caspase-3/7 activity was increased in the treated cells; especially, a significant increase of caspase-3/7 activity was observed in the cells treated with cilengitide and RAMBO and cilengitide combined. There was a significant increase in the activity of caspase-3/7 in the cells treated with the combination therapy compared with RAMBO monotherapy, cilengitide monotherapy and untreated cells (*P ¼ 0.0008, **P ¼ 0.0117, and ***P ¼ 0.0008, respectively). Athymic nude mice bearing intracranial U87DEGFR gliomas were treated with 0.5 Â 10 5 plaque-forming units RAMBO at 7 days after tumor cell implantation. At 9 days after tumor cell implantation, cilengitide was administered three times per week intraperitoneally at 200 mg per 100 ml PBS. The mice were then closely monitored for survival. There was a significant increase in the survival of mice treated with combination therapy compared with RAMBO or cilengitide monotherapy (median survival ¼ 38.5, 29, and 19 days, respectively) (Po0.005 and Po0.001, respectively).
Future directions
Cilengitide monotherapy or combination treatment with radiation and/or temozolomide is well tolerated and exhibits modest antitumor activity. 20, 31, 32 The CENTRIC controlled phase III study was launched in 2008, with primary outcome measures due in September 2012. The results of this and other clinical studies are expected with great hope and interest for combination therapy with an oncolytic virus. In addition, cysteine-rich 61 (CYR61) is known to interact with integrins, such as avb3, a6b1, avb5, and aIIb3, which leads to a wide range of biological activity, including cell adhesion, migration and invasion. 33 Previously, we showed that the induction of CYR61 after oncolysis results in the production of a proangiogenic glioma extracellular matrix that has a key role in the neovascularization of a residual tumor. Moreover, exogenous CYR61 in glioma extracellular matrix is reported to orchestrate a cellular antiviral response that reduces viral replication and limits the efficacy of the oncolytic virus. 34 Future studies will investigate the mechanism of the CYR61-induced antitumor effect of RAMBO and cilengitide combination therapy. Recently, Yoo et al. 35 described the construction and testing of a novel HSV-1-derived oncolytic virus, 34.5ENVE (viral ICP34.5 Expressed by Nestin promoter and Vstat120 Expressing), for the treatment of cancer. We also intend to use this new virus in combination with cilengitide.
In conclusion, our results indicated that cilengitide enhaced vasculostatin-expressing OV therapy for malignant glioma and unveiled a rationale for designing future clinical trials combining these two agents. Figure 8 . Apoptotic pathways whereby rapid antiangiogenesis mediated by oncolytic virus (OV) and cilengitide combination exerts this cytotoxic effect: the mitochondrial pathway and the death receptor pathway.
